Payment overview · 2025
General Payments
$168,807.55
147 reported records · 30 companies
Healthcare provider profile · identity verified
Gaurav Jain, M.D.
Allopathic & Osteopathic Physicians|Neurological Surgery · WYNNEWOOD, PA · NPI 1912206301
Verified facts
What the public records show
CMS Open Payments records show Gaurav Jain, M.D. received $168,807.55 in general payments during 2025 across 147 reported records.
Alphatec Spine, Inc accounted for 92.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alphatec Spine, Inc | Unresolved — no canonical attribution shown | $156,241.73 | 92.6% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $6,663.75 | 4.0% | 58 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $2,325.80 | 1.4% | 11 | 2025 |
| VB Spine LLC | Unresolved — no canonical attribution shown | $1,847.46 | 1.1% | 13 | 2025 |
| Providence Medical Technology, Inc. | Unresolved — no canonical attribution shown | $215.71 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.29 | 0.1% | 8 | 2025 |
| Spinal Elements, INC. | Unresolved — no canonical attribution shown | $134.36 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $123.82 | 0.1% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.55 | 0.1% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $97.85 | 0.1% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $92.54 | 0.1% | 5 | 2025 |
| 4WEB, Inc. | Unresolved — no canonical attribution shown | $90.31 | 0.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $82.22 | 0.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $66.32 | 0.0% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $62.33 | 0.0% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$61.18 | 0.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.02 | 0.0% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $55.31 | 0.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.84 | 0.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.52 | 0.0% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $31.68 | 0.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.61 | 0.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $25.70 | 0.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.88 | 0.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.77 | 0.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.98 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.17 | 0.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.53 | 0.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.35 | 0.0% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $11.97 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $156,883.42 | 6 |
| Consulting Fee | $6,000.00 | 4 |
| Food and Beverage | $5,862.96 | 131 |
| Travel and Lodging | $61.17 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Other - Miscellaneous Normalized: other miscellaneous |
Device | Alphatec Spine, Inc | $156,241.73 | 4 | 2025 |
Source payment records
|
|||||
| EXCELSIUS GPS Normalized: excelsius gps |
Device | Globus Medical, Inc. | $2,454.83 | 27 | 2025 |
Source payment records
|
|||||
| YUKON OCT SPINAL SYSTEM Normalized: yukon oct spinal system |
Device | Stryker Corporation, VB Spine LLC | $1,559.33 | 4 | 2025 |
Source payment records
|
|||||
| OZARK CERVICAL PLATE SYSTEM Normalized: ozark cervical plate system |
Device | Stryker Corporation | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| HILINE Normalized: hiline |
Device | Globus Medical, Inc. | $641.69 | 2 | 2025 |
Source payment records
|
|||||
| SABLE Normalized: sable |
Device | Globus Medical, Inc. | $640.54 | 16 | 2025 |
Source payment records
|
|||||
| N/A Normalized: n a |
Device | Stryker Corporation | $504.02 | 6 | 2025 |
Source payment records
|
|||||
| CREO Normalized: creo |
Device | Globus Medical, Inc. | $487.10 | 14 | 2025 |
Source payment records
|
|||||
| XLIF Normalized: xlif |
Device | Globus Medical, Inc. | $447.65 | 8 | 2025 |
Source payment records
|
|||||
| EVEREST SPINAL SYSTEM Normalized: everest spinal system |
Device | Stryker Corporation, VB Spine LLC | $446.38 | 5 | 2025 |
Source payment records
|
|||||
| FORTIFY Normalized: fortify |
Device | Globus Medical, Inc. | $266.98 | 6 | 2025 |
Source payment records
|
|||||
| RELINE Normalized: reline |
Device | Globus Medical, Inc. | $214.68 | 6 | 2025 |
Source payment records
|
|||||
| HEDRON Normalized: hedron |
Device | Globus Medical, Inc. | $177.37 | 3 | 2025 |
Source payment records
|
|||||
| VUEPOINT Normalized: vuepoint |
Device | Globus Medical, Inc. | $172.34 | 5 | 2025 |
Source payment records
|
|||||
| RISE Normalized: rise |
Device | Globus Medical, Inc. | $148.31 | 3 | 2025 |
Source payment records
|
|||||
| COALITION AGX Normalized: coalition agx |
Device | Globus Medical, Inc. | $144.70 | 2 | 2025 |
Source payment records
|
|||||
| Medical Device Normalized: medical device |
Device | Spinal Elements, INC. | $134.36 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $123.82 | 5 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $120.55 | 2 | 2025 |
Source payment records
|
|||||
| ACP Normalized: acp |
Device | Globus Medical, Inc. | $97.86 | 1 | 2025 |
Source payment records
|
|||||
| CASCADIA INTERBODY SYSTEM Normalized: cascadia interbody system |
Device | VB Spine LLC | $96.06 | 1 | 2025 |
Source payment records
|
|||||
| SI-LOK Normalized: si lok |
Device | Globus Medical, Inc. | $93.95 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $92.54 | 5 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $92.54 | 5 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $92.54 | 5 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $92.54 | 5 | 2025 |
Source payment records
|
|||||
| SPINE TRUSS SYSTEM Normalized: spine truss system |
Device | 4WEB, Inc. | $90.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.92 | 3 | 2025 |
Source payment records
|
|||||
| MODULUS Normalized: modulus |
Device | Globus Medical, Inc. | $83.13 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $82.85 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $82.22 | 3 | 2025 |
Source payment records
|
|||||
| CAPRI CORPECTOMY CAGE SYSTEM Normalized: capri corpectomy cage system |
Device | Stryker Corporation | $77.97 | 1 | 2025 |
Source payment records
|
|||||
| MONTEREY AL Normalized: monterey al |
Device | Stryker Corporation | $77.97 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $69.32 | 4 | 2025 |
Source payment records
|
|||||
| ES2 SPINAL SYSTEM Normalized: es2 spinal system |
Device | VB Spine LLC | $67.47 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $66.32 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $65.55 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $62.33 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $61.02 | 3 | 2025 |
Source payment records
|
|||||
| QUARTEX Normalized: quartex |
Device | Globus Medical, Inc. | $59.19 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.09 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.61 | 2 | 2025 |
Source payment records
|
|||||
| MAGNIFY Normalized: magnify |
Device | Globus Medical, Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Cervical-Stim Normalized: cervical stim |
Device | Orthofix Medical, Inc. | $11.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $168,807.55 · 147 records | Alphatec Spine, Inc | ACP, AMYVID, AUSTEDO XR, BOTOX, CAPRI CORPECTOMY CAGE SYSTEM, CASCADIA INTERBODY SYSTEM, COALITION AGX, CREO, CREXONT, Cervical-Stim, ES2 SPINAL SYSTEM, ETERNA, EVEREST SPINAL SYSTEM, EXCELSIUS GPS, FORTIFY, Gocovri, HEDRON, HILINE, Hizentra, INBRIJA, INGREZZA, KISUNLA, LEQEMBI, MAGNIFY, MODULUS, MONTEREY AL, Medical Device, N/A, NUPLAZID, NURTEC ODT, ONGENTYS, OZARK CERVICAL PLATE SYSTEM, Other - Miscellaneous, QUARTEX, QULIPTA, QUTENZA, RELINE, RISE, SABLE, SI-LOK, SIMPONI, SIMPONI ARIA, SPINE TRUSS SYSTEM, STELARA, TREMFYA, TYSABRI, UBRELVY, ULTOMIRIS, VUEPOINT, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, XLIF, Xeomin, YUKON OCT SPINAL SYSTEM, ZAVZPRET, ZEMBRACE SYMTOUCH, ZENPEP | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error